Miracle Biomedical

CompanyTaiwan

Miracle Biomedical develops one asset, in phase 1 (MiraMSC in frailty). Mostly cell therapy; based in Taiwan.

1
Asset
Furthest stage
Phase 1
1
Trial
0
Signals

Pipeline

1
  • MiraMSC

    Allogeneic umbilical cord-derived mesenchymal stem cell therapy intended to treat frailty.

    Phase 1, Cell therapy, frailty

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals1
  • Similar companies6

Intelligence